<DOC>
	<DOCNO>NCT00915135</DOCNO>
	<brief_summary>The purpose study determine dose response Ramelteon , daily ( QD ) , Japanese subject Chronic Insomnia</brief_summary>
	<brief_title>Efficacy Safety Ramelteon Chronic Insomnia</brief_title>
	<detailed_description>Complaints sleep disorder increase today 's age society change lifestyle . Sleep disorder impact one 's activity daily live , also impede one 's social life , lead reduce productivity sometimes accidents carelessness . Ramelteon melatonin-1 receptor agonist global development Takeda Chemical Industries , Ltd. , Osaka , Japan , treatment transient chronic insomnia treatment Circadian Rhythm Sleep Disorders .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Has primary chronic insomnia least 3 month . Has mean latency great equal 20 minute 2 consecutive polysomnography screen night night le 15 minute , mean least 60 minute wake time across 2 night night le 45 minute . Has habitual bedtime 8:30 PM 12:00 AM . Has body mass index less 17 , less 34 . Females childbearing potential sexually active must agree use medically accept mean contraception , neither pregnant lactating Screening throughout duration study . Has history psychiatric disorder ( include depression anxiety ) , seizures , drug addiction , sleep apnea , nocturnal myoclonus and/or mental retardation define Diagnostic Statistical Manual Mental Disorders , Fourth Edition . Has history alcohol abuse within previous 2 year . Has hepatic disease , significant neurological , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematological metabolic disease . Has know hypersensitivity ramelteon related compound , include melatonin . Has positive hepatitis panel include hepatitis A , hepatitis B hepatitis C. Has clinically abnormal finding determine medical history , physical examination , electrocardiogram clinical laboratory test investigator sub investigator . Has experience 3 hour jet lag within 7 day precede polysomnography screening . Has apneahypopnea index ( per hour sleep ) great equal 10 see first night polysomnography screening . Has periodic limb movement arousal index ( per hour sleep ) great equal 10 see first night polysomnography screening . Has participate excessive weight loss program may give influence evaluation study , alter participant 's exercise routine within 30 day prior doubleblind study medication administration . Has clinically significant illness within 30 day prior doubleblind study medication administration . Has sleep schedule change require employment ( e.g. , shift worker ) within 3 month prior doubleblind study medication administration . The investigator sub investigator judge study subject inappropriate participation consider difficult complete study , participate study best interest subject .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Insomnia</keyword>
	<keyword>Sleep Initiation Maintenance Disorders</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>